CDH17 and cancer: The percentage of CDH17-negative primary cancer and CDH17-positive LN metastasis specimens was 28.6% (4/14), and the percentage of CDH17-negative primary cancer and CDH17-negative LN metastasis specimens was 71.4% (10/14; Table 4).